Kounis syndrome is the concurrence of acute coronary syndromes with conditions associated with mast cell activation ... IgE-mediated diseases (Box 1). Despite cardiovascular symptoms and signs ...

The values for submucosal eosinophil counts, mast-cell counts, and thickness of the basement membrane and lamina reticularis are presented in Figure 1. The median submucosal eosinophil count was 2 ...

Sections were treated with 0.1% trypsin (Sigma ... for 18 h at 4°C with the monoclonal antibody AA1 (anti-human mast cell protease tryptase; DAKO M7052, Dako, Cambridge, UK), washed in TBS ...

It stems from having too many mast cells in the skin, a type of white blood cell involved in the immune system. Understanding ...

Mast cells develop from hematopoietic progenitors in response to stem-cell factor (KIT ligand), which is the ligand of the CD117 transmembrane tyrosine kinase receptor, encoded by KIT. CD117 ...

Mast cell activation syndrome (MCAS) is a condition that occurs when the mast cells in your body release too much of a substance that causes allergy-like symptoms. Mast cells are part of your ...

Mast cell leukemia (MCL) is a quick-progressing condition ... MCL is the rarest form of systemic mastocytosis, making up less than 1 percent of cases. MCL can cause a variety of symptoms including ...

underscoring the importance of treating patients early in the ISM disease course -- -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity ...

8 Mast cells can be activated by several stimuli acting on numerous cell surface receptors. The responses to different stimuli are influenced by a multitude of factors that affect the surface ...

EP262 is a first-in-class, potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation ... conduct a Phase 1 study in the first ...